Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C6H4-1,3-(OH)2
CAS Number:
Molecular Weight:
110.11
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
906905
grade
pharmaceutical primary standard
vapor density
3.8 (vs air)
vapor pressure
1 mmHg ( 21.1 °C)
API family
resorcinol
autoignition temp.
1126 °F
manufacturer/tradename
EDQM
bp
178 °C/16 mmHg (lit.)
mp
109-112 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
Oc1cccc(O)c1
InChI
1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
InChI key
GHMLBKRAJCXXBS-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Resorcinol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Resorcinol
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 3 - Eye Dam. 1 - Skin Irrit. 2 - Skin Sens. 1B - STOT SE 1 Oral - STOT SE 2 Oral
target_organs
Central nervous system,Blood, Respiratory system
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
260.6 °F - closed cup
flash_point_c
127 °C - closed cup
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
50% resorcinol peel.
P G Karam
International journal of dermatology, 32(8), 569-574 (1993-08-01)
Resorcinol.
IARC monographs on the evaluation of carcinogenic risks to humans, 71 Pt 3, 1119-1131 (1999-09-07)
Frank Welsch
International journal of toxicology, 27(1), 59-63 (2008-02-23)
Medical case reports published in the 20th century over the course of several decades show that resorcinol caused reversible adverse effects on the human thyroid gland (TG) manifested as hypothyroidism. Affected patients had ulcerating leg varicosities and underwent prolonged treatment